Stocktoria
Nuo Therapeutics, Inc. AURX
Nuo Therapeutics, Inc. financials (annual)
Bars are annual figures from 2015 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $1.4M | $608,525 | $112,250 | $0 | $0 | $146,177 | $1.4M | $721,045 | $11.5M |
| Gross profit | $2.2M | $1.1M | $482,433 | $93,036 | $0 | $0 | $31,563 | $1.2M | -$369,997 | $3.5M |
| R&D expense | — | — | — | — | $0 | $0 | $181,185 | $576,192 | $1.3M | $2.6M |
| SG&A expense | $4.7M | $3.5M | $3.7M | $3.4M | $90,670 | — | — | — | — | — |
| Operating income | -$2.5M | -$2.5M | -$3.2M | -$3.3M | -$90,670 | -$378,059 | -$969,198 | -$1.5M | -$15.5M | -$41.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | -$89,013 |
| Net income | -$2.5M | -$2.3M | -$3.2M | -$3.2M | -$90,670 | -$90,870 | -$1.2M | -$1.5M | -$15.0M | -$52.8M |
| EPS (diluted) | — | — | — | — | $-0.03 | $0.27 | $-0.05 | $-0.07 | $-1.02 | — |
| Operating cash flow | -$864,971 | -$2.2M | -$3.2M | -$3.7M | -$119,955 | -$53,821 | -$921,674 | -$874,388 | -$4.9M | -$14.4M |
| Free cash flow | -$1.1M | -$2.4M | -$3.2M | -$3.8M | -$119,955 | -$53,821 | -$921,674 | — | — | -$15.1M |
| Cash & equivalents | $548,946 | $283,714 | $928,681 | $2.1M | $1.4M | $161,432 | $20,253 | $636,927 | $693,515 | $922,317 |
| Inventory | $213,761 | $150,442 | $209,589 | $240,005 | $0 | — | — | $25,348 | $35,590 | $254,385 |
| Total assets | $1.8M | $1.2M | $1.9M | $3.0M | $1.5M | $161,432 | $276,548 | $975,497 | $1.4M | $7.1M |
| Total liabilities | $2.8M | $675,796 | $838,732 | $856,022 | $673,079 | $664,951 | $1.5M | $1.1M | $941,168 | $43.1M |
| Shareholders' equity | -$956,559 | $513,712 | $1.0M | $2.2M | $792,839 | -$503,519 | -$1.2M | -$81,987 | $482,871 | -$36.6M |
Growth · year-over-year · Revenue CAGR -12.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +142.7% | +124.3% | +442.1% | — | — | -100.0% | -89.3% | +90.1% | -93.7% | +48.3% |
| EPS growth | — | — | — | — | -111.1% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.